20.500.12556/DiRROS-27506 Case report: long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in prader willi syndrome - case series and literature review Introduction: Prader-Willi syndrome (PWS) is the most prevalent cause of syndromic obesity. Obesity development in PWS is driven by dysfunction in neural pathways involved in satiety and reward, dysregulation in hormones regulating satiety and food intake, altered body composition and reduced energy expenditure, as well as the presence of various hormone deficiencies. As hyperphagia, satiety dysfunction and consequent food-seeking behaviors are intrinsic to PWS, obesity management can be challenging. Case series: We present a long-term follow-up of treatment with GLP-1 receptor agonist (GLP-1 RA) semaglutide in three patients with PWS without diabetes, one of whom had previously undergone metabolic surgery. Semaglutide treatment at dosages from 0.5 mg to 2 mg weekly demonstrated variable efficacy, from preventing further weight gain in patient 1, to achieving weight loss of up to 14.4% and 11% relative to baseline, in Patient 2 and Patient 3. It was well tolerated, even after metabolic surgery. Conclusion: Long-term randomized placebo-controlled trials with larger sample sizes are needed to provide stronger evidence on the long-term efficacy and safety of semaglutide for obesity treatment in PWS as well as explore the potential synergistic effects of GLP-1 RA treatment combined with other therapeutic interventions. Prader-Willi syndrome obesity GLP-1 receptor agonist Prader-Willijev sindrom debelost agonist receptorja GLP-1 true false true Angleški jezik Slovenski jezik Neznano 2026-02-10 14:03:57 2026-02-10 14:03:58 2026-02-11 04:01:11 0000-00-00 00:00:00 2025 0 0 Nasl. z nasl. zaslona; Opis vira z dne 14. 2. 2025; 7 str. Vol. 15, [article no.] 1528457 Jan. 2025 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.4 1664-2392 10.3389/fendo.2024.1528457 223228675 RAZ_Koceva_Andrijana_2025.pdf RAZ_Koceva_Andrijana_2025.pdf 1 3CD2D8FB0FD84E6AB059E0DD3F69655D d8fdc0725ad2cef6df459e3d11292e94c5f20f17117c7dbef0ddb1bc8d59d4fd 1f769265-0681-11f1-bcbc-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=40274 https://www.frontiersin.org/articles/10.3389/fendo.2024.1528457 1 f78d092a-0680-11f1-bcbc-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=40273 Univerzitetni klinični center Ljubljana 0 0 0